국소적으로 재발된 유방암의 경우, 근래에 와서 치료법의 발다로 관해율도 증가되고, 또한 환자의 수명도 연장시킬 수 있다는 보고가 증가되고 아울러 관심도 높아지고 있는 상태이다. 따라서 이런 국소 재발된 유방암을 가진 환자의 특성과 치료에 대한 실패양상, 그리고 예후에 영향을 미치는 인자들을 분석하여 이들 환자에 대한 치료에 도움이 되고자, 서울대학교 병원에서는 1979년에서 1986년까지 치료받은 총 33예에 대해서 분석을 하여 다음과 같은 결과를 얻었다. 15예$(45\%)$에서 흉벽에 국한되어 재발하였고, 18예가 임파절에 재발을 하였다. 초기 치료후 36개월만에 $87\%$가 재발을 보였다. 원전절제를 받아 방사선치료에 대한 판정을 할 수 없었던 8예를 제외한 25예에서 $72\%$(18예)가 방사선치료 후 완전관해를 보였다. 국소재발 후 3년 동안의 생존율은 $50\%$였다. 초기 치료후 2년이내 재발한 환자들의 3년 생존율은 $24\%$였고, 2년 이후 재발한 경우는 $100\%$였다. 흉벽에만 재발한 경우, 3년 생존율은 $57\%$였고, 임파절에만 재발한 경우는 $43\%$였다. 후자의 경우 대부분이 원격전이를 보였다. 완전관해를 보인 예와, 그렇지 않은 예에서는 각각 $63\%$의 3년 생존율, 그리고 $33\%$의 1년 생존율을 보였다. 3명의 환자가 대측 유방에 암을 보였다. 원발성 유방암에 대해서 수술과 전신치료를 함께 받은 경우 3년 생존율이 $40\%$였고, 수술만 시행한 경우는 $71\%$였다. 방사선 치료후 후속적 재발을 보인 경우의 2년 생존율은 $25\%$였다.
Thirty eight women with recurrent breast carcinoma involving chest wall and/or regional lymph nodes after surgery with or without systemic therapy were treated with radiation between 1979 and 1986. Among them, 5 patients were excluded from analysis because of incomplete treatment. The median follow up of survivors was 30 months (randged 1-79 months). Fifteen $(45\%)$ patients had their disease confined to the chest wall and eighteen patients had lymph node involvement as some of their locoregional recurrent disease. Within 36 months after the initial treatment, $87\%$ of recurrences manifested themselves. All patients had radiotherapy to at least the site of involvement. In 8 patients, recurrent tumors were treated with complete excision followed by radiation. Of the remaining 25 patients,18 $(72\%)$ had complete response (CR) following radiotherapy. The actuarial 3-year survival of all patients following locoregional recurrence was $50\%$ Three year survival was $24\%$ in those 25 patients who had recurrences within 24 months of the initial treatment. For those 8 patients whose recurrences occurred after more than 24 month disease free interval, the 3-year survival was $100\%$. For those patients with recurrences confined to chest wall alone, 3-year survival was $57%$ The patients who had lymph node involvement as part of their locoregional recurrences had a $43\%$ 3-year survival. The majority of them developed distant metastases. Those patients who had a CR showed $63\%$ 3-year survival. On the other hand, 1 year survival was only $33\%$ for those patients who had a less than CR. Three patients developed carcinoma of the contralateral breast following radiotherapy. Three year survival following locoregional recurrence was $40\%$ for patients whose initial treatment for their primary breast carcinoma was surgery and adjuvant systemic therapy. For those patients whose primary breast carcinoma was treated by surgery alone, the 3-year survival following locoregional recurrence was $71\%$. In patients who had subsequent recurrence after radiotherapy, the actuarial survival was $25\%$ at 2 years.
